Viewing by:
Existing and emerging biotech advances are transforming the way we preserve and transport donated organs. While their methods may vary, all share a common end
“Is it possible to achieve successful VCA transplantation after 72hrs ischemia at sub-zero temperature?” @X-Therma is pleased to get the answer revealed during the highly
We are honored to be featured in the May Issue of AIChE – American Institute of Chemical Engineers. Special thank you to the National Science
X-Therma was supported early on by the National Science Foundation (NSF) to develop ice-interactive biomimetic nanomaterial to advance biopreservation for unmet needs in Regenerative Medicine. We have
X-Therma is competitively selected for a third US Department of the Army SBIR Phase II SBIR contract. X-Therma’s CryomatrixTM is a new pipeline of non-toxic
X-Therma is competitively selected for a second US Department of Defense Phase II SBIR contract. This contract funds genitourinary organ transplants performed with XT-ViVoTM cryopreserved
X-Therma is featured in “Wirtschaftswoche“ – top weekly magazine in German Economy. —59 Valley Talk: Investoren begeistern sich für Transplantationstechnik, WirtschaftsWoche Ausgabe 42/2016
X-Therma is competitively selected by for a US Department of Defense Phase II SBIR contract. Murine heart transplants will be performed with XT-ViVoTM cryo
X-Therma is granted by U.S. Department of Defense for Phase I research on developing breakthrough cryoprotective agents (CPAs) for large organ/tissue cryopreservation!
"*" indicates required fields
X-Therma, Inc.
2600 Hilltop Drive
Suite B220
Richmond, CA 94806
USA
Kaiserjägerstraße 30
6020 Innsbruck
Austria
2600 Hilltop Drive
Suite B220
Richmond, CA 94806
USA
Kaiserjägerstraße 30
6020 Innsbruck
Austria
